Injection of SPP into a primary tumor appears to facilitate an immune response which may improve clinical benefits reminiscent of those reported in studies where radiation and ablation were used to create an “inflamed” TME that synergizes with immune therapy [47–56]. The gene discussed is HM13; the disease is neoplasm.